Pharma & Healthcare Funding Drops 85.83% in February 2025

This marks a steep decline from $300 million in January 2025, representing a 78.86% drop compared to $201 million in February 2024.

Funding in the healthcare and pharma sector saw a significant drop of 85.83% in February 2025, falling to $42.5 million.

This marks a steep decline from $300 million in January 2025 and represents a 78.86% drop compared to $201 million in February 2024, according to a report by Tracxn.

The report highlights that February 2025 was among the sector's lowest-funded months in the past year.

Early-Stage Rounds Dominate Investments

Despite the decline, early-stage funding accounted for 85.1% of the total investment, raising $34.6 million in February. Seed-stage investments contributed $7.87 million, making up 18.5% of the total funding.

Among the notable funding rounds, MOC secured $18 million, while Apex Kidney Care raised $9 million. Key investors during this period included Elevation Capital, Endiya Partners, and Good Capital.

The decline in funding reflects a cautious investment environment in the healthcare and pharma sector. While early-stage investments continue to attract funding, the significant drop in overall investment levels raises concerns about sustained capital flow in the industry.